Pfizer Centers for Therapeutic Innovation (CTI)

A Translational Medicine Collaboration Opportunity for BU and BMC Researchers

BU and BMC researchers working with validated drug targets that are tractable with biologic modalities such as monoclonal antibodies, peptides or proteins, and are interested in developing a novel therapeutic agent in partnership with pharma should apply.

There will be 3 calls for proposals in 2015 from CTI. The 2015 submission deadlines for a 2-page pre-proposal are February 13th, June 12th, and October 16th.

Therapeutic Areas of Interest:

  • Inflammation
  • Autoimmunity
  • Tissue remodeling
  • Oncology
  • Cancer Immunology
  • Rare or genetic diseases
  • Cardiovascular and metabolic diseases
  • Neuroscience

Key Project Attributes:

  • Demonstrated association between target biology, pathway and disease mechanism
  • Target validation as demonstrated by genetic or pharmacologic evidence
  • Novel target, novel therapeutic strategy or new insight into target patient population

The Process

We encourage interested PI’s to submit a brief abstract describing their project to BU-OTD and we can help assess suitability prior to pre-proposal submission. Then non-confidential pre-proposals should be submitted via email to BU-OTD (see below for link to template). Prior to submission to CTI, we will conduct a review of the pre-proposal to ensure that no confidential or proprietary information is included. CTI will make the decisions on which pre-proposals to advance to a full proposal stage. Invitations will then be sent to the PI‘s to submit confidential full proposals, to be developed together with CTI personnel. Funding decisions on full proposals will be made by the CTI-BU/BMC Joint Steering Committee.

Below are links to documents that provide additional details:

Guidelines for the CTI Program

Flyer Call for Proposals for February 2015

Pre-Proposal Template for Applicants

If you have any questions regarding the program, please contact David Lough, dlough@bu.edu

 About CTI

The Centers for Therapeutic Innovation (CTI) is a pioneering research and development network initiated by pharma that uses an open innovation model to bring great ideas to fruition. Part of Pfizer, we are an entrepreneurial group that partners with leading academic medical centers and disease foundations with the aim of translating promising science into clinical candidates.

More information at: www.pfizercti.com